|  |  |  | **Trimester** | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **T1** | | **T2** | | **T3** | |
|  |  |  | **Exposed** | | | | | |
| Variable name | Variable level | Estimate name | Unexposed | Exposed | Unexposed | Exposed | Unexposed | Exposed |
| Number records | - | N | 882 | 870 | 1,261 | 1,276 | 819 | 816 |
| Age | - | Median [Q25 - Q75] | 33.00 [30.00 - 37.00] | 33.00 [30.00 - 37.00] | 34.00 [31.00 - 37.00] | 34.00 [31.00 - 37.00] | 35.00 [31.00 - 37.50] | 35.00 [31.00 - 37.00] |
| Age group | 12 to 24 | N (%) | 44 (5.0%) | 47 (5.4%) | 46 (3.6%) | 48 (3.8%) | 17 (2.1%) | 14 (1.7%) |
|  | 25 to 39 | N (%) | 748 (84.8%) | 738 (84.8%) | 1,074 (85.2%) | 1,087 (85.2%) | 704 (86.0%) | 704 (86.3%) |
|  | 40 to 55 | N (%) | 90 (10.2%) | 85 (9.8%) | 141 (11.2%) | 141 (11.1%) | 98 (12.0%) | 98 (12.0%) |
| Vaccine brand | Moderna | N (%) | 654 (74.1%) | 642 (73.8%) | 893 (70.8%) | 905 (70.9%) | 525 (64.1%) | 525 (64.3%) |
|  | Pfizer | N (%) | 228 (25.9%) | 228 (26.2%) | 368 (29.2%) | 371 (29.1%) | 294 (35.9%) | 291 (35.7%) |
| Trimester | Trimester 1 | N (%) | 882 (100.0%) | 870 (100.0%) | - | - | - | - |
|  | Trimester 2 | N (%) | - | - | 1,261 (100.0%) | 1,276 (100.0%) | - | - |
|  | Trimester 3 | N (%) | - | - | - | - | 819 (100.0%) | 816 (100.0%) |
| Number visits prior year | - | Median [Q25 - Q75] | 12.00 [6.00 - 24.00] | 22.00 [10.00 - 42.00] | 20.00 [10.00 - 34.00] | 34.00 [20.00 - 54.50] | 26.00 [15.00 - 41.00] | 44.00 [26.00 - 68.00] |
| Number prior pregnancies | - | Median [Q25 - Q75] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] | 1.00 [1.00 - 2.00] | 2.00 [2.00 - 2.00] |
| Conditions any time prior | Anemia | N (%) | 181 (20.5%) | 168 (19.3%) | 252 (20.0%) | 216 (16.9%) | 163 (19.9%) | 169 (20.7%) |
|  | Heart conditions | N (%) | 19 (2.2%) | 16 (1.8%) | 38 (3.0%) | 39 (3.1%) | 24 (2.9%) | 16 (2.0%) |
|  | Eclampsia preeclampsia | N (%) | 5 (0.6%) | 11 (1.3%) | 14 (1.1%) | 12 (0.9%) | 10 (1.2%) | 14 (1.7%) |
|  | Asthma | N (%) | 52 (5.9%) | 56 (6.4%) | 78 (6.2%) | 88 (6.9%) | 46 (5.6%) | 57 (7.0%) |
|  | Pneumonia | N (%) | 17 (1.9%) | 25 (2.9%) | 44 (3.5%) | 31 (2.4%) | 19 (2.3%) | 19 (2.3%) |
|  | Hypothyroidism | N (%) | 73 (8.3%) | 73 (8.4%) | 131 (10.4%) | 135 (10.6%) | 74 (9.0%) | 98 (12.0%) |
|  | Depressive disorder | N (%) | 43 (4.9%) | 53 (6.1%) | 56 (4.4%) | 64 (5.0%) | 41 (5.0%) | 41 (5.0%) |
|  | Gestational diabetes | N (%) | 28 (3.2%) | 41 (4.7%) | 56 (4.4%) | 43 (3.4%) | 60 (7.3%) | 53 (6.5%) |
|  | Chronic hypertension | N (%) | 17 (1.9%) | 30 (3.4%) | 27 (2.1%) | 26 (2.0%) | 19 (2.3%) | 18 (2.2%) |
|  | Anxiety disorder | N (%) | 234 (26.5%) | 214 (24.6%) | 346 (27.4%) | 341 (26.7%) | 230 (28.1%) | 208 (25.5%) |
|  | Chronic obstructive lung disease | N (%) | 0 (0.0%) | <5 (<5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) |
| Drugs prior 180 days | Propulsives | N (%) | 36 (4.1%) | 28 (3.2%) | 41 (3.3%) | 30 (2.4%) | 24 (2.9%) | 12 (1.5%) |
|  | Progestogens | N (%) | 46 (5.2%) | 36 (4.1%) | 86 (6.8%) | 87 (6.8%) | 60 (7.3%) | 49 (6.0%) |
|  | Antimycotics systemic | N (%) | <5 (<5%) | 7 (0.8%) | 6 (0.5%) | <5 (<5%) | <5 (<5%) | <5 (<5%) |
|  | Estrogens | N (%) | 55 (6.2%) | 65 (7.5%) | 63 (5.0%) | 66 (5.2%) | 40 (4.9%) | 34 (4.2%) |
|  | Antithrombotics | N (%) | 40 (4.5%) | 22 (2.5%) | 109 (8.6%) | 83 (6.5%) | 118 (14.4%) | 80 (9.8%) |
|  | Antihistamines systemic | N (%) | 118 (13.4%) | 108 (12.4%) | 200 (15.9%) | 250 (19.6%) | 132 (16.1%) | 129 (15.8%) |
|  | Antidepressants | N (%) | 50 (5.7%) | 51 (5.9%) | 54 (4.3%) | 60 (4.7%) | 26 (3.2%) | 33 (4.0%) |
|  | Immunoglobulins | N (%) | <5 (<5%) | <5 (<5%) | 21 (1.7%) | 26 (2.0%) | 97 (11.8%) | 81 (9.9%) |
|  | Analgesics and antipyretics | N (%) | 255 (28.9%) | 236 (27.1%) | 485 (38.5%) | 435 (34.1%) | 316 (38.6%) | 291 (35.7%) |
|  | Antiinflammatory antirehumatic | N (%) | 233 (26.4%) | 234 (26.9%) | 197 (15.6%) | 177 (13.9%) | 68 (8.3%) | 70 (8.6%) |
|  | Antiepileptics | N (%) | 16 (1.8%) | 18 (2.1%) | 15 (1.2%) | 13 (1.0%) | 9 (1.1%) | 12 (1.5%) |
|  | Antibacterials systemic | N (%) | 166 (18.8%) | 149 (17.1%) | 289 (22.9%) | 250 (19.6%) | 208 (25.4%) | 188 (23.0%) |